SCHEMBL8408100

SCHEMBL8408100

COC1OC(CO)C(OC)C(O)C1N

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 2/20 0.44
▸ AMY2A P04746 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LRAT O95237 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MGAM O43451 2/20 0.38
▸ SI P14410 2/20 0.38
▸ FGF1 P05230 1/20 0.38
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ GJA1 P17302 1/20 0.37
▸ GJB2 P29033 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16362497 1.00 LGALS8 (0.44) LGALS8AMY2AMEN1LRATTRPV1
SCHEMBL18583739 1.00 LGALS8 (0.44) LGALS8AMY2AMEN1LRATTRPV1
SCHEMBL15235669 1.00 LGALS8 (0.44) LGALS8AMY2AMEN1LRATTRPV1
SCHEMBL16784536 1.00 LGALS8 (0.44) LGALS8AMY2AMEN1LRATTRPV1
SCHEMBL13990757 0.94 MEN1 (0.49) AMY2AMEN1LRATTRPV1HSD17B10
SCHEMBL13903853 0.94 MEN1 (0.49) AMY2AMEN1LRATTRPV1HSD17B10
SCHEMBL14639596 0.94 MEN1 (0.49) AMY2AMEN1LRATTRPV1HSD17B10
SCHEMBL17816417 0.94 MEN1 (0.49) AMY2AMEN1LRATTRPV1HSD17B10
SCHEMBL7150867 0.87 LGALS8 (0.47) LGALS8MEN1TSHRLMNAKDM4E
SCHEMBL7150873 0.87 LGALS8 (0.47) LGALS8MEN1TSHRLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148030-A1 KETO ACID BIOPOLYMERS AND POLYOL KETO ESTERS AND USES THEREOF ATOSSA THERAPEUTICS, INC. (US) 2024-07-11 — — WO disclosed
US-20190185588-A1 PHOSPHONIUM-CROSSLINKED CHITOSAN AND METHODS FOR USING AND PRODUCING THE SAME UTI LIMITED PARTNERSHIP (CA) 2019-06-20 — — US disclosed
US-20180142067-A1 MATERIAL AND PREPARATION OF BIOCOMPATIBLE HEMOSTATIC WATER SOLUBLE CHITOSAN COMSATS INSTITUTE OF INFORMATION TECHNOLOGY (PK) 2018-05-24 — — US disclosed
US-9555395-B2 Chemically modified mycological materials having absorbent properties ECOVATIVE DESIGN LLC (US) 2017-01-31 — — US disclosed
US-9555395-B2 Chemically modified mycological materials having absorbent properties ECOVATIVE DESIGN LLC (US) 2017-01-31 — — US disclosed
US-9163338-B2 Fibrous mats containing chitosan nanofibers DREXEL UNIVERSITY (US) 2015-10-20 — — US disclosed
US-20150151005-A1 MICROPARTICLES AND NANOPARTICLES MADE UP OF HYDROPHOBIZED POLYSACCHARIDES AND AN ALPHA-CYCLODEXTRINE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-06-04 — — US disclosed
US-20150038326-A1 Chemically Modified Mycological Materials Having Absorbent Properties ECOVATIVE LLC 2015-02-05 — — US disclosed
US-20150038326-A1 Chemically Modified Mycological Materials Having Absorbent Properties ECOVATIVE LLC 2015-02-05 — — US disclosed
US-20120128781-A1 FUNCTIONALIZATION OF NANOPARTICLES BY GLUCOSAMINE DERIVATIVES YING JACKIE Y (SG) 2012-05-24 — — US disclosed
US-20120128781-A1 FUNCTIONALIZATION OF NANOPARTICLES BY GLUCOSAMINE DERIVATIVES YING JACKIE Y (SG) 2012-05-24 — — US disclosed
US-20100291055-A1 SURGICAL HYDROGEL MEDTRONIC XOMED, INC. 2010-11-18 — — US disclosed
US-20100216211-A1 FIBROUS MATS CONTAINING CHITOSAN NANOFIBERS DREXEL UNIVERSITY (US) 2010-08-26 — — US disclosed
US-7604795-B1 Nanoparticles for protein drug delivery GP MEDICAL, INC. (US) 2009-10-20 — — US disclosed
US-7541046-B1 Nanoparticles for protein drug delivery GP MEDICAL, INC. (US) 2009-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128781-A1 FUNCTIONALIZATION OF NANOPARTICLES BY GLUCOSAMINE DERIVATIVES CSGALNACT1, OGT, ALG1 LGALS8 62/4885AMY2A 3869/4885MEN1 3356/4885
US-20180142067-A1 MATERIAL AND PREPARATION OF BIOCOMPATIBLE HEMOSTATIC WATER SOLUBLE CHITOSAN F12, FGB, PROC LGALS8 576/4885AMY2A 536/4885MEN1 1012/4885
US-20100291055-A1 SURGICAL HYDROGEL CD44, ILK, DSC1 LGALS8 899/4885AMY2A 2115/4885MEN1 4663/4885
US-20150151005-A1 MICROPARTICLES AND NANOPARTICLES MADE UP OF HYDROPHOBIZED POLYSACCHARIDES AND AN ALPHA-CYCLODEXTRINE CD44, CD63, ALG1 LGALS8 574/4885AMY2A 816/4885MEN1 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback